Chapter 8. Tensions in Licensing and Reimbursement Decisions: The Case of Riluzole for Amytrophic Lateral Sclerosis

  1. Nick Freemantle1 and
  2. Suzanne Hill2
  1. Stirling Bryan,
  2. Josie Sandercock,
  3. Pelham Barton and
  4. Amanda Burls

Published Online: 5 NOV 2007

DOI: 10.1002/9780470994719.ch8

Evaluating Pharmaceuticals for Health Policy and Reimbursement

Evaluating Pharmaceuticals for Health Policy and Reimbursement

How to Cite

Bryan, S., Sandercock, J., Barton, P. and Burls, A. (2004) Tensions in Licensing and Reimbursement Decisions: The Case of Riluzole for Amytrophic Lateral Sclerosis, in Evaluating Pharmaceuticals for Health Policy and Reimbursement (eds N. Freemantle and S. Hill), Blackwell Science Ltd, Oxford, UK. doi: 10.1002/9780470994719.ch8

Editor Information

  1. 1

    Department of Primary Care and General Practice, University of Birmingham,Birmingham,UK

  2. 2

    Faculty of Health,University of Newcastle,Newcastle, Australia

Publication History

  1. Published Online: 5 NOV 2007
  2. Published Print: 1 AUG 2004

ISBN Information

Print ISBN: 9780727917843

Online ISBN: 9780470994719

SEARCH

Keywords:

  • amytrophic lateral sclerosis;
  • riluzole;
  • cost-effectiveness;
  • drug licensing;
  • drug reimbursement

Summary

This chapter contains sections titled:

  • Introduction

  • Riluzole for amyotrophic lateral sclerosis

  • The disease

  • The licensing of riluzole

  • The reimbursement decision

  • The review of effectiveness evidence

  • The review of existing cost-effectiveness evidence

  • Further economic analysis

  • Tensions between licensing and reimbursement decisions

  • Licensing versus reimbursement

  • The tension in the case of riluzole

  • Uncertainty, the need to make a decision, and the need for further research: the final tension

  • Conclusion

  • References